Dr Linda Emperatriz Jimenez, MD - Medicare Hospitalist in Aurora, CO

Dr Linda Emperatriz Jimenez, MD is a medicare enrolled "Family Medicine" physician in Aurora, Colorado. She went to University Of Missouri, Kansas City, School Of Medicine and graduated in 2019 and has 5 years of diverse experience with area of expertise as Hospitalist. She is a member of the group practice Colorado Permanente Medical Group Pc and her current practice location is 15101 E Iliff Ave Ste 140, Aurora, Colorado. You can reach out to her office (for appointments etc.) via phone at (720) 878-7055.

Dr Linda Emperatriz Jimenez is licensed to practice in Colorado (license number DR.0067024) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1598320418.

Contact Information

Dr Linda Emperatriz Jimenez, MD
15101 E Iliff Ave Ste 140,
Aurora, CO 80014-4548
(720) 878-7055
Not Available



Physician's Profile

Full NameDr Linda Emperatriz Jimenez
GenderFemale
SpecialityHospitalist
Experience5 Years
Location15101 E Iliff Ave Ste 140, Aurora, Colorado
Accepts Medicare AssignmentsYes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Dr Linda Emperatriz Jimenez attended and graduated from University Of Missouri, Kansas City, School Of Medicine in 2019
  NPI Data:
  • NPI Number: 1598320418
  • Provider Enumeration Date: 05/06/2019
  • Last Update Date: 01/30/2024
  Medicare PECOS Information:
  • PECOS PAC ID: 3274915772
  • Enrollment ID: I20220731000062

Medical Identifiers

Medical identifiers for Dr Linda Emperatriz Jimenez such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1598320418NPI-NPPES
029376OtherCOKAISER COMMERCIAL NUMBER

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
208M00000XHospitalist DR.0067024 (Colorado)Secondary
207Q00000XFamily Medicine DR.0067024 (Colorado)Primary

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
Colorado Permanente Medical Group Pc12542384541113

News Archive

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

Making Cancer History seminar to take place on Feb. 11

Cancer experts from The University of Texas MD Anderson Cancer Center return to West Palm Beach Feb. 11 for the institution's annual Making Cancer History seminar. The event, in the Cohen Pavilion of the Raymond F. Kravis Center for the Performing Arts, 701 Okeechobee Blvd., begins at 8:30 a.m. with a breakfast buffet.

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

Read more Medical News

› Verified 8 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Linda Emperatriz Jimenez allows following entities to bill medicare on her behalf.
Entity NameInpatient Services, Pc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1710999768
PECOS PAC ID: 5496651267
Enrollment ID: O20031211000419

News Archive

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

Making Cancer History seminar to take place on Feb. 11

Cancer experts from The University of Texas MD Anderson Cancer Center return to West Palm Beach Feb. 11 for the institution's annual Making Cancer History seminar. The event, in the Cohen Pavilion of the Raymond F. Kravis Center for the Performing Arts, 701 Okeechobee Blvd., begins at 8:30 a.m. with a breakfast buffet.

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

Read more Medical News

› Verified 8 days ago

Entity NameCatholic Health Initiatives Colorado
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1356783351
PECOS PAC ID: 8022927342
Enrollment ID: O20031215000462

News Archive

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

Making Cancer History seminar to take place on Feb. 11

Cancer experts from The University of Texas MD Anderson Cancer Center return to West Palm Beach Feb. 11 for the institution's annual Making Cancer History seminar. The event, in the Cohen Pavilion of the Raymond F. Kravis Center for the Performing Arts, 701 Okeechobee Blvd., begins at 8:30 a.m. with a breakfast buffet.

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

Read more Medical News

› Verified 8 days ago

Entity NameColorado Permanente Medical Group Pc
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1760599724
PECOS PAC ID: 1254238454
Enrollment ID: O20031216000640

News Archive

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

Making Cancer History seminar to take place on Feb. 11

Cancer experts from The University of Texas MD Anderson Cancer Center return to West Palm Beach Feb. 11 for the institution's annual Making Cancer History seminar. The event, in the Cohen Pavilion of the Raymond F. Kravis Center for the Performing Arts, 701 Okeechobee Blvd., begins at 8:30 a.m. with a breakfast buffet.

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

Read more Medical News

› Verified 8 days ago

Entity NameHospitalist Medicine Physicians Of Colorado-tcg
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1053890533
PECOS PAC ID: 3072981125
Enrollment ID: O20221121001014

News Archive

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

Making Cancer History seminar to take place on Feb. 11

Cancer experts from The University of Texas MD Anderson Cancer Center return to West Palm Beach Feb. 11 for the institution's annual Making Cancer History seminar. The event, in the Cohen Pavilion of the Raymond F. Kravis Center for the Performing Arts, 701 Okeechobee Blvd., begins at 8:30 a.m. with a breakfast buffet.

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

Read more Medical News

› Verified 8 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Linda Emperatriz Jimenez is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Dr Linda Emperatriz Jimenez, MD
15101 E Iliff Ave Ste 140,
Aurora, CO 80014-4548

Ph: (720) 878-7055
Dr Linda Emperatriz Jimenez, MD
15101 E Iliff Ave Ste 140,
Aurora, CO 80014-4548

Ph: (720) 878-7055

News Archive

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

New journal to focus on autoimmune disease research and development

Springer is launching a new journal Autoimmunity Highlights, an independent, international, peer-reviewed journal that publishes papers related to the diverse aspects of autoimmunity, and seeks to be a bridge between the clinic, the laboratory and the specialists who are involved in the complex world of autoimmunity diagnosis.

Study documents altruistic behavior by human embryonic stem cells

When most groups of mammalian cells are faced with a shortage of nutrients or oxygen, the phrase "every man for himself" is more apt than "all for one, one for all." Unlike colonies of bacteria, which often cooperate to thrive as a group, mammalian cells have never been observed to help one another out. But a new study led by a researcher at the Stanford University School of Medicine has shown that certain human embryonic stem cells, in times of stress, produce molecules that not only benefit themselves, but also help nearby cells survive.

Making Cancer History seminar to take place on Feb. 11

Cancer experts from The University of Texas MD Anderson Cancer Center return to West Palm Beach Feb. 11 for the institution's annual Making Cancer History seminar. The event, in the Cohen Pavilion of the Raymond F. Kravis Center for the Performing Arts, 701 Okeechobee Blvd., begins at 8:30 a.m. with a breakfast buffet.

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

Read more News

› Verified 8 days ago


Family Medicine Doctors in Aurora, CO

Heather Brougham, D.O.
Family Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 12605 E 16th Ave, Aurora, CO 80045
Phone: 720-848-0000    
Dr. Marcus Ian Ng, MD
Family Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 16290 E Quincy Ave, Aurora, CO 80015
Phone: 303-338-4545    
Dr. Vanessa Rosalie Herring, D.O.
Family Medicine
Medicare: Accepting Medicare Assignments
Practice Location: 12631 E 17th Ave Ste F496, Aurora, CO 80045
Phone: 303-724-9700    
Kayley Swope, MD
Family Medicine
Medicare: Medicare Enrolled
Practice Location: 12605 E 16th Ave, Aurora, CO 80045
Phone: 720-848-0000    
Betty Mabel Martinez, MD
Family Medicine
Medicare: Medicare Enrolled
Practice Location: 13701 E Mississippi Ave, Suite 200, Aurora, CO 80012
Phone: 303-398-6340    
Stephen Loyd,
Family Medicine
Medicare: Not Enrolled in Medicare
Practice Location: 12605 E 16th Ave, Aurora, CO 80045
Phone: 303-493-7000    
Dr. Daniel Hurtt, MD
Family Medicine
Medicare: Medicare Enrolled
Practice Location: 275 S Aspen St, Aurora, CO 80011
Phone: 720-847-7658    Fax: 720-847-7480

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.